Deutsche Bank analyst on upgrade
Deutsche Bank has issued an optimistic forecast for Eli Lilly (LLY) and raised the pharmaceutical stock’s rating from “Hold” to “Buy.” The price target was raised by $300 to a total of $1,025 per share. James Shin, an analyst at Deutsche Bank, explains the pharmaceutical company’s forecast and outlook at Catalysts. Shin says the biggest […]